Sorafenib-induced Hand- Foot Skin Reaction Treatment

Rash Clinical Trial

Official title:
Four-arm Study to Evaluate Urea 40% Cream, Fluocinonide 0.05% Cream, Tazarotene 0.1% Cream, and an Emollient Cream for the Treatment of Hand-foot Skin Reaction Related to the Use of Multi-targeted Tyrosine Kinase Inhibitor Sorafenib.

Status Terminated

Clinical Trial Summary

The purpose of this study is to evaluate treatments for a rash caused by sorafenib.

Clinical Trial Description

This study will compare compare the effectiveness of four creams (urea 40% cream, fluocinonide 0.05% cream, tazarotene 0.1% cream, and Udderly smooth® Udder Cream) in treating hand-foot skin reaction (HFSR), a rash caused by sorafenib. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00667589
Study type	Interventional
Source	Northwestern University
Contact
Status	Terminated
Phase	Phase 2
Start date	June 2008
Completion date	December 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05247333` - Implementation of a Minor Ailment Service in Community Pharmacy Practice	N/A
Terminated	`NCT00343187` - A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash	Phase 2
Completed	`NCT00473083` - Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer	Phase 2
Completed	`NCT02326467` - Pilot Study: Safety of Chlorhexidine (CHG) Baths in Patients Less Than 2 Months of Age	Phase 1
Recruiting	`NCT01692626` - 1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX	Phase 2
Completed	`NCT05461456` - Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%	Phase 1